RxDoctor Payments Data

Jaime Martinez Martinez, MD

Ophthalmology · Miami, FLNPI 1790287191

Payments from drug & device makers

$6,008in general payments, 2019–2025

Across 42 payments — averaging $143.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec Digital Innovations LLC$3K
  • Johnson & Johnson Surgical Vision, Inc.$1K
  • Bausch & Lomb Americas Inc.$639
  • Carl Zeiss Meditec USA, Inc.$373
  • Sun Pharmaceutical Industries Inc.$253
  • Dompe US, Inc.$241
  • plus $678 from 13 others

What the payments were for

  • Food & beverage$3,21654%
  • Other$2,79246%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,008 in reported general payments places this provider in the 70th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$425,086
Medicare patients
903
Services billed
2,849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine56$58,119
TyrvayaVarenicline Tartrate49$44,762
MieboPerfluorohexyloctane/Pf48$35,501
XiidraLifitegrast17$20,649
Prednisolone Acetate535$17,731
Cyclosporine25$12,586
ValacyclovirValacyclovir Hcl89$4,683
Ketorolac Tromethamine272$4,241
Loteprednol Etabonate31$3,998
MoxifloxacinMoxifloxacin Hcl196$3,932
Dorzolamide-TimololDorzolamide/Timolol/Pf12$2,452
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim207$1,532
Doxycycline Hyclate61$1,288
Brimonidine Tartrate55$982
Latanoprost106$846

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Miebo, Xiidra$639$56,15065 claims
Oyster Point Pharma, Inc.Tyrvaya$31$44,76249 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →